Announcement
Modulari-T Bioscience Announces a Research Collaboration with a Leading Global Biopharmaceutical Company for a Novel In Vivo CAR-T Program
Montreal, Canada– September, 2026 – Modulari-T, a biotechnology company pioneering next-generation in vivo cell therapies for oncology and autoimmune disorders, announces a research collaboration with a global top 10 pharma company on a novel in vivo CAR-T program against an undisclosed solid tumor cancer target.
“We are truly delighted to be collaborating with our esteemed new partner on this exciting project”, said Tanya Borsuk, Ph.D., Chief Executive Officer at Modulari-T. “Our proprietary MARC and MoVE platforms were built on the premise that an in-depth knowledge of the modular structure and function of native immune receptors is required to unlock the true power of CAR-T technologies. These technologies offer First- and Best-in-Class opportunities deliver a highly novel programs that surmount the limitations of competitor technologies”
The collaboration is supported by CQDM under the Quantum Leap program.
“CQDM is pleased to have facilitated the establishment of collaborations for Modulari-T by creating beneficial links with the Global Biopharmaceutical community. These links between early-stage Canadian companies and the biopharmaceutical industry are critical for the growth of the Canadian life sciences sector,” said Jesse Paterson, Senior Director, Strategy and Pharmaceutical Alliances.
About Modulari-T Biosciences
Modulari-T was founded to harness the power of modular immune receptors for second generation in vivo cell and gene therapies by combining modular immune receptor engineering with custom-designed delivery vectors. The company is creating a new class of cell therapy treatments that are more precise, durable, and scalable across a range of diseases not previously accessible to first generation technology. Its proprietary MARC and MoVe technologies are designed to overcome the limitations of traditional CAR-T and gene therapy approaches with the goal of rendering these treatments more effective and accessible to patients worldwide.
About CQDM
Biopharma Innovation Facilitator
CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate collaborative multi-stakeholder research and development aimed at accelerating the translation or transformation of innovative technologies into solutions to unmet medicalneeds, while generating significant benefits for the Quebec and Canadian economy. For more information, consult our website www.cqdm.org and join us on LinkedIn
Media Contact:
Julia Serafino
Marketing and Communications Director
CQDM
438-543-9498
[email protected]
MODULARI-T
Lauren Arnold
LA Communications
[email protected]
